898808-83-8

Upstream product

• 898808-82-7 4-benzyloxy-2-[1,3]dioxolan-2-yl-5-methoxybenzonitrile 

Downstream Products

• 898808-89-4 3-(4-benzyloxy-5-methoxy-2-methoxymethoxymethylphenyl)-6,7-dimethoxy-2-methyl-2H-isoquinolin-1-one 
• 898808-87-2 3-(4-benzyloxy-5-methoxy-2-methoxymethoxymethylphenyl)-6,7-dimethoxy-2H-isoquinolin-1-one 
• 898808-92-9 3-(4-benzyloxy-2-hydroxymethyl-5-methoxy-phenyl)-6,7-dimethoxy-2-methyl-2H-isoquinolin-1-one 
• 898808-94-1 5-benzyloxy-2-(6,7-dimethoxy-2-methyl-1-oxo-1,2-dihydroisoquinolin-3-yl)-4-methoxybenzaldehyde 
• 898808-85-0 4-benzyloxy-5-methoxy-2-methoxymethoxymethylbenzonitrile 
• 898808-84-9 4-benzyloxy-2-hydroxymethyl-5-methoxybenzonitrile 

Relevant academic research and scientific papers

NOVEL CATECHOL DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, USE OF THE CATECHOL DERIVATIVE AND USE OF THE PHARMACEUTICAL COMPOSITION

The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 and R2 are each hydrogen, lower acyl, lower alkoxycarbonyl or the like; R3 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl or the like; R4 is cyano, lower alkoxycarbonyl, carboxy or the like, which exhibit potent COMT inhibitory activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

Total synthesis of oxyfagaronine, phenolic benzo[c]phenanthridine and general synthetic way of 2,3,7,8- and 2,3,8,9-tetrasubstituted benzo[c]phenanthridine alkaloids

Benzo[c]phenanthridine alkaloids such as oxynitidine, oxysanguinarine, oxyavicine and phenolic oxyfagaronine were synthesized from easily available starting benzonitriles 5 and toluamides 6 using a lithiated toluamidebenzonitrile cycloaddition reaction. T